Literature DB >> 21625299

Hepatitis C-related arthropathy: Diagnostic and treatment considerations.

Nyingi M Kemmer1, Kenneth E Sherman.   

Abstract

Hepatitis C-related arthropathy is one of the most common extrahepatic manifestations of hepatitis C virus (HCV) infection. Although symptoms can be disabling, the prognosis typically is benign. Patients who have atypical chronic inflammatory arthritis with an unknown cause should be evaluated for HCV infection. Testing for antibodies against cyclic citrullinated peptide is useful for distinguishing HCV-related arthropathy from rheumatoid arthritis. Early recognition of HCV infection greatly influences the selection of drug therapy. Although no clinical guidelines are available, many liver disease specialists favor using a stepwise approach to treatment. Future research efforts that focus on the pathogenesis of HCV-related arthropathy and novel therapeutic approaches are needed. (J Musculoskel Med. 2010;27:351-354).

Entities:  

Year:  2010        PMID: 21625299      PMCID: PMC3103264     

Source DB:  PubMed          Journal:  J Musculoskelet Med        ISSN: 0899-2517


  13 in total

Review 1.  American Gastroenterological Association technical review on the management of hepatitis C.

Authors:  Jules L Dienstag; John G McHutchison
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

Authors:  David Saadoun; Mathieu Resche Rigon; Damien Sene; Benjamin Terrier; Alexandre Karras; Laurent Perard; Yoland Schoindre; Brigitte Coppéré; François Blanc; Lucile Musset; Jean-Charles Piette; Michele Rosenzwajg; Patrice Cacoub
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

5.  Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

Authors:  P Cacoub; T Poynard; P Ghillani; F Charlotte; M Olivi; J C Piette; P Opolon
Journal:  Arthritis Rheum       Date:  1999-10

Review 6.  Management of hepatitis C virus-related arthritis.

Authors:  E Zuckerman; D Yeshurun; I Rosner
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

7.  Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  Douglas Lienesch; Robert Morris; Allan Metzger; Paige Debuys; Kenneth Sherman
Journal:  J Rheumatol       Date:  2005-03       Impact factor: 4.666

8.  Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.

Authors:  Mark H Wener; Kathleen Hutchinson; Chihiro Morishima; David R Gretch
Journal:  Arthritis Rheum       Date:  2004-07

Review 9.  Glucocorticosteroids for viral hepatitis C.

Authors:  J Brok; M T Mellerup; K Krogsgaard; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

View more
  7 in total

1.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

Review 2.  Extrahepatic immune related manifestations in chronic hepatitis C virus infection.

Authors:  Maria Tampaki; John Koskinas
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 3.  Viral arthritis.

Authors:  Michael Marks; Jonathan L Marks
Journal:  Clin Med (Lond)       Date:  2016-04       Impact factor: 2.659

4.  Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in taiwan.

Authors:  Fu-Hsiung Su; Chien-Sheng Wu; Fung-Chang Sung; Shih-Ni Chang; Chien-Tien Su; Ying-Hua Shieh; Chih-Ching Yeh
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

5.  Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.

Authors:  Isabela Siloşi; Lidia Boldeanu; Viorel Biciuşcă; Maria Bogdan; Carmen Avramescu; Citto Taisescu; Vlad Padureanu; Mihail Virgil Boldeanu; Anica Dricu; Cristian Adrian Siloşi
Journal:  Int J Mol Sci       Date:  2017-06-19       Impact factor: 5.923

Review 6.  Reactive arthritis before and after the onset of the COVID-19 pandemic.

Authors:  Dana Bekaryssova; Marlen Yessirkepov; Olena Zimba; Armen Yuri Gasparyan; Sakir Ahmed
Journal:  Clin Rheumatol       Date:  2022-03-05       Impact factor: 3.650

7.  Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database.

Authors:  Chien-Hsueh Tung; Ning-Sheng Lai; Chung-Yi Li; Shiang-Jiun Tsai; Yen-Chun Chen; Yi-Chun Chen
Journal:  BMJ Open       Date:  2018-07-23       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.